Contact

Our portfolio

AlpENa Biosciences

Innovating cancer therapeutics, AlpENa Biosciences develops bispecific antibodies that activate immune cells to target and destroy tumor cells. Their research, based on the work of Professor Marjolein van Egmond, shows promising potential in a variety of oncology treatments. The company is backed by Versant Ventures in order to advance these therapies.

  • Institute: Amsterdam UMC
Industry: Oncology, Therapeutics
  • Founding year: 2023
Visit website

Want to get in contact about AlpENa Biosciences?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.
Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.
Explore full AAV portfolio
Contact